Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 641

1.

CRISPR/Cas9: a double-edged sword when used to combat HIV infection.

Liang C, Wainberg MA, Das AT, Berkhout B.

Retrovirology. 2016 May 27;13(1):37. doi: 10.1186/s12977-016-0270-0. No abstract available.

2.

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.

Pham HT, Mesplède T, Wainberg MA.

Retrovirology. 2016 Apr 30;13(1):31. doi: 10.1186/s12977-016-0265-x.

3.

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.

Anstett K, Cutillas V, Fusco R, Mesplède T, Wainberg MA.

J Antimicrob Chemother. 2016 Apr 15. pii: dkw109. [Epub ahead of print]

PMID:
27084918
4.

CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape.

Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S, Wainberg MA, Liang C.

Cell Rep. 2016 Apr 19;15(3):481-9. doi: 10.1016/j.celrep.2016.03.042. Epub 2016 Apr 7.

5.

Might dolutegravir be part of a functional cure for HIV?

Wainberg MA, Han YS, Mesplède T.

Can J Microbiol. 2016 May;62(5):375-82. doi: 10.1139/cjm-2015-0725. Epub 2016 Jan 27.

PMID:
27031127
6.

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.

Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplède T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA.

J Antimicrob Chemother. 2016 Jul;71(7):1948-53. doi: 10.1093/jac/dkw071. Epub 2016 Mar 29.

PMID:
27029845
7.

Early HIV treatment to forestall drug resistance.

Wainberg MA.

Lancet Infect Dis. 2016 Jan 28. pii: S1473-3099(16)00013-X. doi: 10.1016/S1473-3099(16)00013-X. [Epub ahead of print] No abstract available.

8.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

9.

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy.

Wainberg MA, Mesplede T.

J Int AIDS Soc. 2015 Dec 4;18:20824. doi: 10.7448/IAS.18.1.20824. eCollection 2015. No abstract available.

10.

Flueggether A and Virosinine A, Anti-HIV Alkaloids from Flueggea virosa.

Zhang H, Zhu KK, Han YS, Luo C, Wainberg MA, Yue JM.

Org Lett. 2015 Dec 18;17(24):6274-7. doi: 10.1021/acs.orglett.5b03320. Epub 2015 Dec 3.

PMID:
26632657
11.

Has the world ceased to care about HIV? And what can we do about it?

Wainberg MA, Kippax S, Bras M, Sow PS.

J Int AIDS Soc. 2015 Dec 1;18:20818. doi: 10.7448/IAS.18.1.20818. eCollection 2015. No abstract available.

12.

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection.

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group.

N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1.

13.

Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase.

Xu HT, Colby-Germinario SP, Hassounah S, Quashie PK, Han Y, Oliveira M, Stranix BR, Wainberg MA.

Antimicrob Agents Chemother. 2015 Nov 16;60(1):600-8. doi: 10.1128/AAC.02203-15.

14.

Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.

Sluis-Cremer N, Wainberg MA, Schinazi RF.

Future Microbiol. 2015;10(11):1773-82. doi: 10.2217/fmb.15.106. Epub 2015 Oct 30.

PMID:
26517190
15.

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Hassounah SA, Liu Y, Quashie PK, Oliveira M, Moisi D, Brenner BG, Sandstrom PA, Mesplède T, Wainberg MA.

J Virol. 2015 Dec;89(23):12002-13. doi: 10.1128/JVI.02131-15. Epub 2015 Sep 16.

16.

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.

Oliveira M, Mesplède T, Moïsi D, Ibanescu RI, Brenner B, Wainberg MA.

AIDS. 2015 Nov;29(17):2255-60. doi: 10.1097/QAD.0000000000000866.

PMID:
26372484
17.

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

Liang J, Mesplède T, Oliveira M, Anstett K, Wainberg MA.

J Virol. 2015 Nov;89(22):11269-74. doi: 10.1128/JVI.01881-15. Epub 2015 Aug 26.

18.
19.

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.

Mesplède T, Quashie PK, Hassounah S, Osman N, Han Y, Liang J, Singhroy DN, Wainberg MA.

AIDS. 2015 Jul 31;29(12):1459-66. doi: 10.1097/QAD.0000000000000752.

PMID:
26244385
20.

Natural killer cell education does not affect the magnitude of granzyme B delivery to target cells by antibody-dependent cellular cytotoxicity.

Isitman G, Lisovsky I, Tremblay-McLean A, Parsons MS, Shoukry NH, Wainberg MA, Bruneau J, Bernard NF.

AIDS. 2015 Jul 31;29(12):1433-43. doi: 10.1097/QAD.0000000000000729.

PMID:
26244383
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk